MedTrace Logo

MVX-ONCO-1 in Patients With Solid Tumor

NCT02193503 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2023-09-28

No results posted yet for this study

Summary

The objectives are to assess the safety and tolerability of 6 vaccine doses of MVX-ONCO-1, administered sub-cutaneously (injections and capsules implantations), in patients with advanced metastatic solid tumor in progression who are not or not any longer amenable to any standard therapy of their tumour disease.

Conditions

Interventions

OTHER

Treatment

Treatment is the implantation of loaded capsules + injection of irradiated autologous tumor cells

Sponsors & Collaborators

  • Maxivax SA

    lead INDUSTRY

Principal Investigators

  • Eugenio Fernandez, MD · HUG

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2022-03-31
Completion
2026-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02193503 on ClinicalTrials.gov